Skip to main content


Thanks to our excellent research, we are identifying new channels and solutions for boosting the population’s health and well-being.

The VHIR is one of the best research institutes at the national level. The Innovation Unit is currently managing 90 innovation projects, 22% of which are at the fund-raising stage, 9% at the analysis stage, 30% at the implementation stage and 17% at the transfer stage while 22% are in the market, as licences, spin-offs, companies or exclusivity agreements.

Our aim is for the research conducted at the Vall d’Hebron Research Institute (VHIR) to become a driving force for transformation, in the following ways: 

  • by creating an impact on the health and quality of life of patient and society
  • by generating social and economic wealth responsibly and sustainably
  • by becoming a global benchmark for new health ecosystems

It was with this goal in mind that the VHIR has created its own innovation model which is centred on guiding research and knowledge generation towards unresolved clinical challenges and needs as well as creating innovative solutions for meeting them. 

Our innovation strategy is based on:

  • Enhancing and transferring knowledge, with a business vision that enables us to maximise its impact on society and its financial return, to generate more knowledge.
  • Bringing flexibility to and consolidating collaboration with the business fabric, including all the necessary players, and with an international vision and scope.
  • International positioning of our research and VHIR as a centre of excellence.
  • Implementation of our own innovation model which enables faster and increased transfers of the knowledge generated.

Innovation step-to-step

Get to know our Spin-Offs

Knowledge and technology offer

Fetoscopia Surgery Synthetic physical model for high fidelity surgical simulation of fetoscopic spina bifida surgery.
Sintrocito Infectious diseases Design of an agglutination inhibition technique using synthetic erythrocytes for influenza virus surveillance.
MLC_Gen_Tx Neurology Gene therapy for the treatment of an orphan disease, Megaloencephalic leukoencephalopathy with subcortical cysts (MLC).
Bi-AuNPs HIV, Oncology Biofunctionalized gold nanoparticles polarized with two different antibodies, which can promote cell-to-cell contact and target some of the current limitations of immunotherapy.
Cardiocalp Cardiology Specific calpain inhibitor with water solubility and high bioavailability for the prevention and/or treatment of adverse ventricular remodeling
CollyriuNP Ophthalmology Development of an antioxidant nanoparticle-enriched liquid for the treatment of age-related macular degeneration
DPP4 OftalmoloOphthalmologygia Typical ocular treatment for macular neurodegeneration. Particularly useful in early stages of diabetic retinopathy, as well as other retinal diseases in which neurodegeneration plays a major role
Inhib-MNKancer Oncology Inhibition of MNKs may provide a non-toxic and effective strategy for the treatment of cancer, especially in combination with already approved treatments
miRNAs Oncology Novel nanocarries, Quatsomes, has been designed and conjugated with a tummor suppressive miRNA for the treatment of cancer, such as high-risk neuroblastoma
Salivomics Oncology Identification of genetic markers in saliva to improve the early detection of ovarian cancer
Livercolor Hepatology App of colorimetry and Machine Learning that allows to generate a predictive model of hepatic steatosis grading, with better results than the ocular evaluation and that serves as a support tool for the clinical decision of the surgeon performing the transplant
Simoons Teaching Software in Serious Games format, where health or assistance personnel can connect and train their non-technical skills applied to their assistance tasks
Ocular Organoids

Corporate collaborations

grifols logo
genesis logo
gain logo
chameleon logo
invivo logo
anaxomics logo
roche diagnostics
prodigest logo empresas
stimulo logo empresas
onalabs logo empresas
Amplo logo empresas
inkemia logo empresa
keralty logo empresa
landsteiner logo empresas
medical simulator logo empresa
NBD logo empresa

Related news

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

VHIR organises the first meeting between entrepreneurs and the investment ecosystem.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.


Please fill in the fields with the necessary data so we can get in touch with you to solve any questions or queries you may have.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
I've read and I accept the privacy policy
I want to receive information and communications from VHIR
The Vall d’Hebron University Hospital Foundation - Research Institute (VHIR) will process your personal data for the management of your consultation. For more information on the processing of your data, see the VHIR Privacy Policy. You can exercise your rights of access, rectification, deletion, limitation, opposition and portability by notifying the Data Protection Officer ( or the VHIR Legal Unit (